#Ponce De Leon Health #Rejuvant #Aging Cell Study

Rejuvant Rises Above Other Supplements in Groundbreaking Aging Research

Ponce De Leon Health (PDLH) has recently made headlines with the publication of a pivotal study in the scientific journal Aging Cell, demonstrating that its supplement, Rejuvant, significantly outperforms other commonly used products in reducing biological age. Conducted with a large cohort of over 4,000 individuals, this independent study sheds light on the efficacy of various supplements in the quest for longevity.

Study Overview

The study aimed to evaluate the impact of 84 different supplements, drugs, and compounds on biological age, using a DNA methylation clock to standardize results. The primary goal was to determine the effectiveness of these products in slowing the aging process — a subject of interest for many seeking to extend their healthspan.

Among all tested supplements, Rejuvant stood out decisively. Participants who consumed this delayed-release blend of CaAKG and essential vitamins exhibited an average biological age that was 1.8 years lower than expected. This finding not only reached statistical significance, but also positioned Rejuvant as the primary endpoint of the study. In contrast, those taking standard CaAKG or other NAD+ variants, such as NMN or NR, experienced effects that were insignificant and considerably weaker, with the latter proving nine times less effective than Rejuvant.

Insights from Experts

Dr. Brian Kennedy, the Director of the Center for Healthy Longevity at the National University of Singapore and one of the study's authors, applauded the comprehensive nature of the research.